肌肉减少性肥胖在癌症中的研究进展

doi:10.12114/j.issn.1007-9572.2023.0264

摘要/Abstract

摘要： 随着世界范围内肥胖和老年人口的增加，肌肉减少性肥胖正在成为与多种临床环境（包括癌症）中不良事件和结局风险较高的相关因素。但目前对于肌肉减少性肥胖的定义及诊断缺乏统一标准，且其与癌症之间的相互作用关系有待进一步阐明。本文系统、全面地总结了肌肉减少性肥胖的相关定义及诊断方法，将其对癌症患者的临床影响展开具体论述，包括对手术及化疗患者的影响，并总结其主要防治策略。本文总结文献得出，肌肉减少性肥胖在癌症患者中发生率较高，但目前对于其定义及诊断标准仍具有争议。肌肉减少性肥胖是癌症预后的独立预测因素，具有重要临床应用价值。

关键词: 肿瘤, 肌肉减少症, 肥胖, 肌肉减少性肥胖, 预后, 综述

Abstract:

As the number of obese and elderly population increases worldwide, sarcopenic obesity is becoming associated with a higher risk of adverse events and outcomes in multiple clinical situations, including cancer. However, there is a lack of unified definition and diagnostic criteria for sarcopenic obesity, and the interaction between sarcopenic obesity and cancer needs to be further clarified. This paper systematically and comprehensively summarizes the relevant definitions and diagnostic methods of sarcopenic obesity, discusses its clinical impact on cancer patients in detail, including the impact on patients undergoing surgery and chemotherapy, and briefly describes the main prevention and treatment strategies. This paper reviews literature and concludes that the incidence of sarcopenic obesity is high in cancer patients, but its definition and diagnostic criteria are still controversial. Sarcopenic obesity is an independent predictor of cancer prognosis with important clinical application value.

Key words: Neoplasms, Sarcopenia, Obesity, Sarcopenic obesity, Prognosis, Review

彭磊,朱克祥. 肌肉减少性肥胖在癌症中的研究进展[J]. 中国全科医学, 2024, 27(06): 643-649. DOI: 10.12114/j.issn.1007-9572.2023.0264.
PENG Lei,ZHU Kexiang. Research Progress of Sarcopenic Obesity in Cancer[J]. Chinese General Practice, 2024, 27(06): 643-649. DOI: 10.12114/j.issn.1007-9572.2023.0264.

图/表 1

参考文献 67

[1]	WU C C，LI M N，MENG H B，et al. Analysis of status and countermeasures of cancer incidence and mortality in China[J]. Sci China Life Sci，2019，62（5）：640-647. DOI：10.1007/s11427-018-9461-5.
[2]	TAKEDA T，SASAKI T，OKAMOTO T，et al. Prognostic impact of osteosarcopenia in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel[J]. Pancreatology，2023，23（3）：275-282. DOI：10.1016/j.pan.2023.02.002.
[3]	CRUZ-JENTOFT A J，BAHAT G，BAUER J，et al. Sarcopenia：revised European consensus on definition and diagnosis[J]. Age Ageing，2019，48（4）：601. DOI：10.1093/ageing/afz046.
[4]	CHAN M Y，CHOK K S H. Sarcopenia in pancreatic cancer - effects on surgical outcomes and chemotherapy[J]. World J Gastrointest Oncol，2019，11（7）：527-537. DOI：10.4251/wjgo.v11.i7.527.
[5]	ROUBENOFF R. Excess baggage：sarcopenia，obesity，and cancer outcomes[J]. Lancet Oncol，2008，9（7）：605-607. DOI：10.1016/S1470-2045(08)70160-8.
[6]	SANDINI M，BERNASCONI D P，FIOR D，et al. A high visceral adipose tissue-to-skeletal muscle ratio as a determinant of major complications after pancreatoduodenectomy for cancer[J]. Nutrition，2016，32（11/12）：1231-1237. DOI：10.1016/j.nut.2016.04.002.
[7]	PECORELLI N，CARRARA G，DE COBELLI F，et al. Effect of sarcopenia and visceral obesity on mortality and pancreatic fistula following pancreatic cancer surgery[J]. Br J Surg，2016，103（4）：434-442. DOI：10.1002/bjs.10063.
[8]	KIM Y M，KIM J H，BAIK S J，et al. Sarcopenia and sarcopenic obesity as novel risk factors for gastric carcinogenesis：a health checkup cohort study[J]. Front Oncol，2019，9：1249. DOI：10.3389/fonc.2019.01249.
[9]	CARNEIRO I P，MAZURAK V C，PRADO C M. Clinical implications of sarcopenic obesity in cancer[J]. Curr Oncol Rep，2016，18（10）：62. DOI：10.1007/s11912-016-0546-5.
[10]	DONINI L M，BUSETTO L，BISCHOFF S C，et al. Definition and diagnostic criteria for sarcopenic obesity：ESPEN and EASO consensus statement[J]. Obes Facts，2022，15（3）：321-335. DOI：10.1159/000521241.
[11]	BARACOS V E，ARRIBAS L. Sarcopenic obesity：hidden muscle wasting and its impact for survival and complications of cancer therapy[J]. Ann Oncol，2018，29（Suppl 2）：ii1-9. DOI：10.1093/annonc/mdx810.
[12]	MIJNARENDS D M，MEIJERS J M M，HALFENS R J G，et al. Validity and reliability of tools to measure muscle mass，strength，and physical performance in community-dwelling older people：a systematic review[J]. J Am Med Dir Assoc，2013，14（3）：170-178. DOI：10.1016/j.jamda.2012.10.009.
[13]	FARON A，SPRINKART A M，KUETTING D L R，et al. Body composition analysis using CT and MRI：intra-individual intermodal comparison of muscle mass and myosteatosis[J]. Sci Rep，2020，10（1）：11765. DOI：10.1038/s41598-020-68797-3.
[14]	MOURTZAKIS M，PRADO C M M，LIEFFERS J R，et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care[J]. Appl Physiol Nutr Metab，2008，33（5）：997-1006. DOI：10.1139/H08-075.
[15]	MONTANO-LOZA A J，ANGULO P，MEZA-JUNCO J，et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis[J]. J Cachexia Sarcopenia Muscle，2016，7（2）：126-135. DOI：10.1002/jcsm.12039.
[16]	PRADO C M M，LIEFFERS J R，MCCARGAR L J，et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts：a population-based study[J]. Lancet Oncol，2008，9（7）：629-635. DOI：10.1016/S1470-2045(08)70153-0.
[17]	CHO W K，YU J I，PARK H C，et al. Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy[J]. Tumori，2021，107（3）：247-253. DOI：10.1177/0300891620937795.
[18]	SUGAWARA K，YAMASHITA H，OKUMURA Y，et al. Relationships among body composition，muscle strength，and sarcopenia in esophageal squamous cell carcinoma patients[J]. Support Care Cancer，2020，28（6）：2797-2803. DOI：10.1007/s00520-019-05110-7.
[19]	JANG M，PARK H W，HUH J，et al. Predictive value of sarcopenia and visceral obesity for postoperative pancreatic fistula after pancreaticoduodenectomy analyzed on clinically acquired CT and MRI[J]. Eur Radiol，2019，29（5）：2417-2425. DOI：10.1007/s00330-018-5790-7.
[20]	RICKLES A S，IANNUZZI J C，MIRONOV O，et al. Visceral obesity and colorectal cancer：are we missing the boat with BMI?[J]. J Gastrointest Surg，2013，17（1）：133-143；discussionp.143. DOI：10.1007/s11605-012-2045-9.
[21]	KIMURA Y，YAMADA M，OHJI S，et al. Presence of sarcopenic obesity and evaluation of the associated muscle quality in Japanese older men with prostate cancer undergoing androgen deprivation therapy[J]. J Geriatr Oncol，2019，10（5）：835-838. DOI：10.1016/j.jgo.2019.03.017.
[22]	YAMANE H，ABE T，AMANO H，et al. Visceral adipose tissue and skeletal muscle index distribution predicts severe pancreatic fistula development after pancreaticoduodenectomy[J]. Anticancer Res，2018，38（2）：1061-1066. DOI：10.21873/anticanres.12323.
[23]	BATSIS J A，VILLAREAL D T. Sarcopenic obesity in older adults：aetiology，epidemiology and treatment strategies[J]. Nat Rev Endocrinol，2018，14（9）：513-537. DOI：10.1038/s41574-018-0062-9.
[24]	FACCIORUSSO A，ANTONINO M，MUSCATIELLO N. Sarcopenia represents a negative prognostic factor in pancreatic cancer patients undergoing EUS celiac plexus neurolysis[J]. Endosc Ultrasound，2020，9（4）：238-244. DOI：10.4103/eus.eus_24_20.
[25]	KHAN I M，PERRARD X Y，BRUNNER G，et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance[J]. Int J Obes （Lond），2015，39（11）：1607-1618. DOI：10.1038/ijo.2015.104.
[26]	BHULLAR A S，ANOVEROS-BARRERA A，DUNICHAND-HOEDL A，et al. Lipid is heterogeneously distributed in muscle and associates with low radiodensity in cancer patients[J]. J Cachexia Sarcopenia Muscle，2020，11（3）：735-747. DOI：10.1002/jcsm.12533.
[27]	MINTZIRAS I，MILIGKOS M，WÄCHTER S，et al. Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer：systematic review and meta-analysis[J]. Int J Surg，2018，59：19-26. DOI：10.1016/j.ijsu.2018.09.014.
[28]	BIOLO G，CEDERHOLM T，MUSCARITOLI M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases：from sarcopenic obesity to cachexia[J]. Clin Nutr，2014，33（5）：737-748. DOI：10.1016/j.clnu.2014.03.007.
[29]	DOYLE S L，LYSAGHT J，REYNOLDS J V. Obesity and post-operative complications in patients undergoing non-bariatric surgery[J]. Obes Rev，2010，11（12）：875-886. DOI：10.1111/j.1467-789X.2009.00700.x.
[30]	REISINGER K W，DERIKX J P M，VAN VUGT J L A，et al. Sarcopenia is associated with an increased inflammatory response to surgery in colorectal cancer[J]. Clin Nutr，2016，35（4）：924-927. DOI：10.1016/j.clnu.2015.07.005.
[31]	BEAVERS K M，HSU F C，HOUSTON D K，et al. The role of metabolic syndrome，adiposity，and inflammation in physical performance in the Health ABC Study[J]. J Gerontol A Biol Sci Med Sci，2013，68（5）：617-623. DOI：10.1093/gerona/gls213.
[32]	国家卫生健康委员会. 胰腺癌诊疗规范（2018年版）[J].中华消化病与影像杂志（电子版），2019，9（5）：224-240.DOI10.3877/cma.j.issn.1674-0793.2019.04.001.
[33]	ARGILÉS J M，BUSQUETS S，STEMMLER B，et al. Cachexia and sarcopenia：mechanisms and potential targets for intervention[J]. Curr Opin Pharmacol，2015，22：100-106. DOI：10.1016/j.coph.2015.04.003.
[34]	TILG H，MOSCHEN A R. Adipocytokines：mediators linking adipose tissue，inflammation and immunity[J]. Nat Rev Immunol，2006，6（10）：772-783. DOI：10.1038/nri1937.
[35]	SATO H，CARVALHO G，SATO T，et al. The association of preoperative glycemic control，intraoperative insulin sensitivity，and outcomes after cardiac surgery[J]. J Clin Endocrinol Metab，2010，95（9）：4338-4344. DOI：10.1210/jc.2010-0135.
[36]	KURITA Y，KOBAYASHI N，TOKUHISA M，et al. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy[J]. Pancreatology，2019，19（1）：127-135. DOI：10.1016/j.pan.2018.11.001.
[37]	COUSIN S，HOLLEBECQUE A，KOSCIELNY S，et al. Low skeletal muscle is associated with toxicity in patients included in phase I trials[J]. Invest New Drugs，2014，32（2）：382-387. DOI：10.1007/s10637-013-0053-6.
[38]	YIP C，GOH V，DAVIES A，et al. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer[J]. Eur Radiol，2014，24（5）：998-1005. DOI：10.1007/s00330-014-3110-4.
[39]	PRADO C M M，BARACOS V E，MCCARGAR L J，et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity[J]. Clin Cancer Res，2007，13（11）：3264-3268. DOI：10.1158/1078-0432.CCR-06-3067.
[40]	EMORI T，ITONAGA M，ASHIDA R，et al. Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gemcitabine and nab-paclitaxel chemotherapy[J]. Pancreatology，2022，22（2）：277-285. DOI：10.1016/j.pan.2021.12.013.
[41]	TSAI S. Importance of lean body mass in the oncologic patient[J]. Nutr Clin Pract，2012，27（5）：593-598. DOI：10.1177/0884533612457949.
[42]	YOUN S，CHEN A，HA V，et al. An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel[J]. Clin Nutr，2021，40（8）：4888-4892. DOI：10.1016/j.clnu.2021.06.026.
[43]	BAXEVANIS C N，PEREZ S A，PAPAMICHAIL M. Cancer immunotherapy[J]. Crit Rev Clin Lab Sci，2009，46（4）：167-189. DOI：10.1080/10408360902937809.
[44]	YOUSEFI H，YUAN J D，KESHAVARZ-FATHI M，et al. Immunotherapy of cancers comes of age[J]. Expert Rev Clin Immunol，2017，13（10）：1001-1015. DOI：10.1080/1744666X.2017.1366315.
[45]	CHENG A L，HSU C，CHAN S L，et al. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma[J]. J Hepatol，2020，72（2）：307-319. DOI：10.1016/j.jhep.2019.09.025.
[46]	PASQUARELLI-DO-NASCIMENTO G，MACHADO S A，DE CARVALHO J M A，et al. Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy[J]. Immunother Adv，2022，2（1）：ltac015. DOI：10.1093/immadv/ltac015.
[47]	CLOUGHESY T F，MOCHIZUKI A Y，ORPILLA J R，et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma[J]. Nat Med，2019，25（3）：477-486. DOI：10.1038/s41591-018-0337-7.
[48]	CORTELLINI A，BERSANELLI M，BUTI S，et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors：when overweight becomes favorable[J]. J Immunother Cancer，2019，7（1）：57. DOI：10.1186/s40425-019-0527-y.
[49]	WANG Z M，AGUILAR E G，LUNA J I，et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade[J]. Nat Med，2019，25（1）：141-151. DOI：10.1038/s41591-018-0221-5.
[50]	MULLEN M，GONZALEZ-PEREZ R R. Leptin-induced JAK/STAT signaling and cancer growth[J]. Vaccines，2016，4（3）：26. DOI：10.3390/vaccines4030026.
[51]	KICHENADASSE G，MINERS J O，MANGONI A A，et al. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer[J]. JAMA Oncol，2020，6（4）：512-518. DOI：10.1001/jamaoncol.2019.5241.
[52]	CORTELLINI A，BOZZETTI F，PALUMBO P，et al. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors：a multicenter real-life study[J]. Sci Rep，2020，10（1）：1456. DOI：10.1038/s41598-020-58498-2.
[53]	DALY L E，POWER D G，O'REILLY A，et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma[J]. Br J Cancer，2017，116（3）：310-317. DOI：10.1038/bjc.2016.431.
[54]	GUO Y S，REN Y Q，WU F H，et al. Prognostic impact of sarcopenia in patients with hepatocellular carcinoma treated with PD-1 inhibitor[J]. Therap Adv Gastroenterol，2022，15：17562848221142417. DOI：10.1177/17562848221142417.
[55]	KANO M，HIHARA J，TOKUMOTO N，et al. Association between skeletal muscle loss and the response to nivolumab immunotherapy in advanced gastric cancer patients[J]. Int J Clin Oncol，2021，26（3）：523-531. DOI：10.1007/s10147-020-01833-4.
[56]	SHIROYAMA T，NAGATOMO I，KOYAMA S，et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors：a preliminary retrospective study[J]. Sci Rep，2019，9（1）：2447. DOI：10.1038/s41598-019-39120-6.
[57]	TOZUKA Y，UENO M，KOBAYASHI S，et al. Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel：a retrospective study[J]. Oncol Lett，2022，24（4）：375. DOI：10.3892/ol.2022.13495.
[58]	LODEWICK T M，VAN NIJNATTEN T J A，VAN DAM R M，et al. Are sarcopenia，obesity and sarcopenic obesity predictive of outcome in patients with colorectal liver metastases?[J]. HPB，2015，17（5）：438-446. DOI：10.1111/hpb.12373.
[59]	KOBAYASHI A，KAIDO T，HAMAGUCHI Y，et al. Impact of sarcopenic obesity on outcomes in patients undergoing hepatectomy for hepatocellular carcinoma[J]. Ann Surg，2019，269（5）：924-931. DOI：10.1097/SLA.0000000000002555.
[60]	CHARGI N，BRIL S I，SWARTZ J E，et al. Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma[J]. Oral Oncol，2020，101：104519. DOI：10.1016/j.oraloncology.2019.104519.
[61]	SOLHEIM T S，LAIRD B J A，BALSTAD T R，et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer[J]. J Cachexia Sarcopenia Muscle，2017，8（5）：778-788. DOI：10.1002/jcsm.12201.
[62]	RICHTER E，DENECKE A，KLAPDOR S，et al. Parenteral nutrition support for patients with pancreatic cancer—improvement of the nutritional status and the therapeutic outcome[J]. Anticancer Res，2012，32（5）：2111-2118.
[63]	KEMMLER W，KOHL M，FRÖHLICH M，et al. Effects of high-intensity resistance training on osteopenia and sarcopenia parameters in older men with osteosarcopenia-one-year results of the randomized controlled Franconian osteopenia and sarcopenia trial （FrOST）[J]. J Bone Miner Res，2020，35（9）：1634-1644. DOI：10.1002/jbmr.4027.
[64]	PRADO C M，PURCELL S A，LAVIANO A. Nutrition interventions to treat low muscle mass in cancer[J]. J Cachexia Sarcopenia Muscle，2020，11（2）：366-380. DOI：10.1002/jcsm.12525.
[65]	WITARD O C，WARDLE S L，MACNAUGHTON L S，et al. Protein considerations for optimising skeletal muscle mass in healthy young and older adults[J]. Nutrients，2016，8（4）：181. DOI：10.3390/nu8040181.
[66]	FLOREZ BEDOYA C A，CARDOSO A C F，PARKER N，et al. Exercise during preoperative therapy increases tumor vascularity in pancreatic tumor patients[J]. Sci Rep，2019，9（1）：13966. DOI：10.1038/s41598-019-49582-3.
[67]	KIRK B，ZANKER J，DUQUE G. Osteosarcopenia：epidemiology，diagnosis，and treatment-facts and numbers[J]. J Cachexia Sarcopenia Muscle，2020，11（3）：609-618. DOI：10.1002/jcsm.12567.